Top

Gepubliceerd in:

2009 | OriginalPaper | Hoofdstuk

15 Medicamenteus-toxisch leverlijden

Auteur : Prof.dr. J. Fevery

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Toxisch leverlijden kan in allerlei vormen tot uiting komen en wordt veroorzaakt door inname, inhalatie of injectie van medicatie, kruiden of chemicaliën.^[1] In dit hoofdstuk worden de incidentie, de aard, de ontstaansmechanismen en het stellen van de diagnose besproken.

vorige hoofdstuk 14 Metabole leverziekten

volgende hoofdstuk 16 Levertumoren

Pessayre D, Larrey D, Biour M. Drug-induced liver injury. In: Bircher, et al., Oxford Textbook of Clinical Hepatology, pp. 1261–1315. Oxford Med Public, 1999.

Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474–485.PubMedCrossRef

Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451–455.PubMedCrossRef

Olsson R, Brunlof G, Johansson ML, Persson M. Druginduced hepatic injury in Sweden. Hepatology 2003; 38:531–532.PubMedCrossRef

Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Patchkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005;129:512–521.PubMedCrossRef

Wood AJJ. Developmental pharmacology – drug disposition, action, and therapy in infants and children. New Engl J Med 2003;349:1157–1167.CrossRef

Marshall E. Guilty plea puts Oraflex case to rest. Science 1985;229:1071.PubMed

Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, Rabkin JM, Lee WM. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transpl Surg 1999;5:480–484.PubMedCrossRef

McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:1099–1105.PubMedCrossRef

10.

Wagenaar LJ, Kuck EM, Hoekstra JB. Troglitazone. Is it all over? Neth J Med 1999;55:4–12.PubMedCrossRef

11.

Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005;41:237–246.PubMedCrossRef

12.

But PPH. Herbal poisoning caused by adulterants or erroneous substitutes. J Trop Med Hygiene 1994;97: 371–374.

13.

Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005;43:901–910.PubMedCrossRef

14.

Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38(Suppl 2):S44–S48.PubMedCrossRef

15.

Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481–489.PubMedCrossRef

16.

Nagato K, Yamazoe Y. Genetic polymorphism of human cytochrome P 450 involved in drug metabolism. Drug Metabol Pharmacokin 2002:17;167–189.CrossRef

17.

Nelson SD. Molecular mechanism of hepatotoxicity caused by acetaminophen. Sem Liver Dis 1990;90:267.CrossRef

18.

Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22:767–773.PubMedCrossRef

19.

Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB 3rd. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976;193:901–903.PubMedCrossRef

20.

Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975;18:70–79.PubMed

21.

Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the US population: Gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40:827–835.PubMedCrossRef

22.

Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003;307:117–128.PubMedCrossRef

23.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of Irinotecan. J Clin Oncol 2004:1382–1388.

24.

Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23(Suppl. 1):16–24.PubMed

25.

Van Pelt FNAM, Straub P, Manns MP. Molecular basis of drug induced immunological liver injury. Semin Liv Dis 1995;15:283–300.CrossRef

26.

Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997;26(Suppl 1):23–30.PubMedCrossRef

27.

Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou JP. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 1982;31:1699–1704.PubMedCrossRef

28.

Geneve J, Hayat-Bonan B, Labbe G, Degott C, Letteron P, Freneaux E, Dinh TL, Larrey D, Pessayre D. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 1987;242:1133–1137.PubMed

29.

Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999;15:367–373.PubMedCrossRef

30.

Faber KN, Műller M, Janssen PLM. Drug transport proteins in the liver. Adv Drug Delivery Reviews 2003; 55:107–124.CrossRef

31.

Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007;1773:283–308.PubMedCrossRef

32.

Geubel AP, Sempoux C. Drug and toxin-induced bile duct disorders. J Gastroent & Hep 2000;15:1232–1238.

33.

Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356–1359.PubMedCrossRef

34.

Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003;23:405–409.PubMedCrossRef

35.

Pham BN, Bernuau J, Durnand F, Sauvanet A, Degott C, Prin L, Janin A. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol 2001;34:537–547.PubMedCrossRef

36.

Report of an International Consensus Meeting. Criteria of drug-induced liver disorders. J Hepatol 1990;11: 272–276.

37.

Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, De La Cuesta FS. Comparison of two clinical scales for causality assessment on hepatotoxicity. Hepatology 2001;33:123–130.PubMedCrossRef

38.

Zimmerman HJ. Hepatotoxicity. New York: Appleton- Century-Crofts, 1978.

39.

Stricker BHC. Drug-induced Hepatic Injury. Amsterdam: Elsevier, 1992.

40.

Farrell GC. Drug-induced Liver Injury. New-York: Chruchill Livingstone, 1994.

41.

Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. New York/Basel: Marcel Dekker, 2003.

42.

Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PS, Rahier J, Geubel AP. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181–1186.PubMedCrossRef

43.

Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:373–380.PubMedCrossRef

44.

Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, et al. HLA class II genotype influences the type of liver injury in drug induced idiosyncratic liver disease. Hepatology 2004;39:1603–1612.PubMedCrossRef

45.

Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018–1023.PubMedCrossRef

46.

Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991;100:1701–1709.PubMed

47.

Labbe G, Descatoire V, Letteron P, Degott C, Tinel M, Larrey D, Carrion-Pavlov Y, Geneve J, Amouyal G, Pessayre D. The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity of carbon tetrachloride in mice. Biochem Pharmacol 1987;36:907–914.PubMedCrossRef

48.

Nevens F, Fevery J, Van Steenbergen W, Sciot R, Desmet V, De Groote J. Arsenic and non-cirrhotic portal hypertension. A report of eight cases. J Hepatol 1990; 11:80–85.PubMedCrossRef

Titel: 15 Medicamenteus-toxisch leverlijden
Auteur: Prof.dr. J. Fevery
Uitgeverij: Bohn Stafleu van Loghum
Boek: Leverziekten
Print ISBN: 978-90-313-7436-6

Elektronisch ISBN: 978-90-313-7437-3

Copyright: 2009
DOI: https://doi.org/10.1007/978-90-313-7437-3_15

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen